apoC-I CRISPR/Cas9 KO Plasmid (m): sc-419163
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- apoC-I CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the apoC-I genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
apoC-I CRISPR/Cas9 KO Plasmid (m) | sc-419163 | 20 µg | $397.00 |
Overview
Apoc1 encodes apolipoprotein C-I (apoC-I), a small secreted apolipoprotein that associates with HDL and VLDL particles and modulates lipid transport and lipoprotein remodeling. In mice, apoC-I influences the balance of triglyceride-rich lipoprotein clearance and cholesterol trafficking by affecting receptor interactions and lipase-dependent processing within the circulating lipoprotein pathway. Apoc1 expression is enriched in macrophage-lineage cells and can shape innate immune signaling programs linked to lipid handling. Dysregulated APOC1 biology has been connected to atherosclerosis-relevant inflammation, metabolic dyslipidemia, and neuroinflammatory contexts, supporting its use in mechanistic studies of immunometabolism.
apoC-I CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Apoc1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Apoc1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Apoc1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish apoC-I protein expression.
This CRISPR knockout system enables efficient generation of Apoc1-deficient cell models for investigation of apoC-I signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Apoc1 exon(s) critical for apoC-I function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Apoc1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by apoC-I CRISPR/Cas9 KO Plasmid (m) and apoC-I CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Apoc1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by apoC-I HDR Plasmid (m) and apoC-I HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Apoc1 homology arms to support homology-directed repair at defined Apoc1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.